The passenger leukocyte hypothesis predicts that after transplantation, donor antigen-presenting cells (APCs) from the graft present donor MHC molecules to directly alloreactive T cells in lymphoid organs. However, in certain transplantation models, recent evidence contradicts this long-standing concept. New findings demonstrate that host, instead of donor, APCs play a prominent role in allosensitization against donor MHC molecules via the semidirect pathway. A similar mechanism operates in development of T-cell split tolerance to noninherited maternal antigens.
INTRODUCTION
The cellular adaptive immune response against allografts is mediated through recognition by donor-reactive T cells of donor intact allo-major histocompatibility complex (MHC) molecules presented by donor cells -via the direct pathway of allorecognition-, and of self-MHC molecules loaded with peptides derived from polymorphic regions of the donor MHC molecules or of non-MHC proteins, the latter known as the indirect pathway. More recently, it became evident that directly alloreactive T cells also recognize donor MHC molecules acquired intact by recipient antigen-presenting cells (APCs) through a third mechanism known as the semidirect pathway.
It has been classically accepted that after organ/tissue transplantation, donor leukocytes transplanted with the graft -mainly conventional dendritic cells-, become activated and migrate as 'passenger leukocytes' via lymphatic or blood vessels to the draining lymph nodes or spleen, respectively, where they supposedly present by themselves donor intact MHC molecules to directly alloreactive T cells [1, 2] . This concept, which to our knowledge has not been formally proven, has been challenged in recent years. Indeed, donor-derived dendritic cells are undetectable or found at extremely low numbers in graftdraining lymphoid organs during the first week after transplantation of fully H2-mismatched skin, pancreatic islets or heart allografts in mice [3 && ,4 && ]. Apart from this, once they leave the graft, donor-migrating dendritic cells have a short lifespan and, in fully allogeneic models, they could become targets of recipient natural killer cells and cytotoxic T cells (CTLs) [5] [6] [7] [8] . Importantly, the lymphatic vessels of the grafts -one of the main exit routes of passenger leukocytes -are cut off during surgery, and they fully reconnect with the recipient lymphatic vasculature days after transplantation, once the antidonor T-cell response has been already elicited [4 && ]. Therefore, if no or extremely low number of donor-migrating APCs traffic to the graft-draining lymphoid organs, how directly alloreactive T cells become activated so rapidly and efficiently after transplantation? Two recent studies have independently demonstrated in mouse models that, although donor-migrating APCs are difficult to detect in graft-draining lymphoid organs after heart or skin transplantation, a relatively high number of recipient APCs resident in the draining lymphoid organs carry on their cell surface donor intact MHC class-I and class-II molecules [3 && ,4 && ]. These recipient APCs cross-dressed with donor MHC molecules triggered via the semidirect pathway, activation and effector cell-differentiation of directly alloreactive T cells in the graft-draining lymphoid organs.
Passage of intact MHC molecules between allogeneic cells
The fact that APCs acquire allogeneic MHC molecules from other leukocytes or endothelial cells is not novel. It is well established that leukocytes transfer surface molecules, including MHC molecules, through one or multiple mechanisms that have been termed cross-dressing, trogocytosis or cell nibbling, based on the experimental model analyzed and cell types involved in the molecular transfer. Indeed, Herrera et al. [9] originally postulated cross-dressing of recipient conventional dendritic cells with donor MHC molecules as the basis of the semidirect pathway of T-cell allorecognition in transplantation. Experiments in which donor and recipient (acceptor) dendritic cells were separated by 0.4 mm pore size membranes suggested that although not essential, cell-to-cell contact increases substantially transfer of intact MHC molecules between dendritic cells [9] . Since this seminal study, donor MHC molecules have been detected on the surface of recipient APCs resident in graft-draining lymphoid organs following heart and kidney transplantation in mice [10, 11] . After bone marrow transplantation in mice, donor dendritic cells acquire recipient MHC molecules, which indicates that the passage of MHC molecules between donor and recipient APCs in vivo is bidirectional [12] . Despite these relevant findings, the ultimate mechanism(s) by which recipient APCs acquire and retain on the cell surface donor MHC molecules with the right topology for presentation to directly alloreactive T cells, and the impact that the resulting semidirect pathway of allorecognition exerts in graft rejection have remained relatively unexplored until recently. The new and rapidly expanding field of extracellular vesicles -in particular exosomes-as mediators of intercellular communication, is currently providing new answers to these long-standing questions in the transplantation field [13] .
Extracellular vesicles: membrane couriers between cells
Cells communicate with each other through the release of soluble mediators, cell-to-cell contact via surface receptor-ligand interactions and, as more recently discovered, by exchanging extracellular vesicles, which differ in biogenesis, vesicle size and molecular composition [14] . It seems likely that
KEY POINTS
In some transplant models (e.g. fully mismatch skin or heart allografts in untreated mice), donor passenger leukocytes are absent or detected at very low numbers in the draining lymphoid organs. during evolution, transfer of extracellular vesicles was one of the primordial mechanisms of cell-tocell communication before the development of more sophisticated mechanisms of cellular interaction such as binding of surface membrane receptors with its ligands [15] . The term extracellular vesicles include microvesicles, nanovesicles (i.e. exosomes), vesicles released by cells undergoing apoptosis (i.e. apoptotic cell blebs and apoptotic bodies) and other extracellular vesicles not well defined yet [16, 17] (Table 1 ). Microvesicles are released by shedding of the plasma membrane of living cells, range in size between 0.2 and 1 mm, and are also known as microparticles or ectosomes [14] . Exosomes are produced within the endocytic compartment of living cells and are between 30 and 120 nm in diameter [13, 14] . Exosomes are generated as intraluminal vesicles by reverse budding of the limiting membrane of early endosomes, which are then termed multivesicular bodies. Exosomes are released to the extracellular milieu when the limiting membrane of the multivesicular body fuses with the cell membrane. Exosomes can also originate within Golgi-apparatus-derived vesicles generated for exocytosis. Once secreted by the parent cells, exosomes bind or are internalized by acceptor cells, attach to the extracellular matrix, or traffic passively through lymph, blood or other bodily fluids.
Because there is very limited information regarding the role of microvesicles and apoptotic cell-derived extracellular vesicles on recognition of nonself-MHC molecules in transplantation, the rest of the review will be focused mainly on exosomes. Exosomes, as other extracellular vesicles, function as carriers for horizontal propagation of nucleic acids, proteins and likely lipids and carbohydrates between cells. The composition of exosomes depends on the lineage and stage of activation/differentiation, infection and transformation of the parent cells. Exosomes also carry proteins that are preferentially enriched on the surface or in the lumen of the extracellular vesicles (e.g. the tetraspanins CD9 and CD63, tumor susceptibility gene 101 and syntenin-1), which are commonly used as exosome markers [17] . Exosomes also contain in their lumen functional mRNAs, noncoding RNAs (e.g. microRNAs), and even extrachromosomal DNA (e.g. amplified MYC). Exosomes have cell-independent ability to process precursor miRNAs into mature miRNAs within the extracellular vesicles [18] . By fusing with the target cells, exosomes deliver their cargo of functional mRNAs, regulatory RNAs and proteins into the cytosol of the acceptor cells [19] [20] [21] . Transfer of miRNAs and proteins through exosomes and other extracellular vesicles, between cancer cells and the tumor microenvironment and draining lymphoid tissues, participates in tumor initiation, invasion, angiogenesis, premetastasis niche formation, drug resistance and immune escape [22] . Because, to some extent, the RNA and protein content of extracellular vesicles reflect that of the parent cells, extracellular vesicles isolated from bodily fluids (e.g. plasma and urine) could be used as potential diagnostic and prognostic biomarkers in cancer, and in infectious or metabolic diseases, and as predictive biomarkers of transplant rejection [23,24 & ]. The potential use of extracellular vesicles as platforms to deliver biomolecules to target cells for therapeutic applications is an active area of research [25, 26] . Exosomes derived from mature and immature dendritic cells have been used, in combination with other therapies, to stimulate or suppress the immune response in humans and murine models [27, 28] .
Interestingly for the field of transplantation, the surface membrane of exosomes released by activated professional APCs is highly enriched in antigenpresenting molecules (e.g. MHC class-I and class-II), T-cell costimulatory molecules (CD86) and APC T-cell adhesion molecules (e.g. CD54) with their binding domains topologically oriented toward the outer side of the extracellular vesicles [13] . Although APC-derived exosomes, at relatively high concentrations, can function as antigen-presenting vesicles for T-cell clones and memory T cells, their capability to stimulate by themselves naive T cells is rather weak [13] . In contrast, the potency of APCderived exosomes to stimulate naive T cells increases substantially when the extracellular vesicles are attached to APCs [13] . Exosomes released by activated/matured APCs (i.e. mature exosomes) carry higher content of surface MHC antigen, CD54 and CD86, and are more potent T-cell stimulators, compared with exosomes secreted by quiescent APCs (i.e. immature exosomes) [29, 30] . Moreover, nonprofessional APCs cross-dressed with mature exosomes released by professional APCs acquire the ability to stimulate naive T cells [29] . The capacity of graft-derived exosomes -and likely other types of extracellular vesicles -to transfer nonself-MHC antigen and APC-activating mediators to the recipient APCs seems to be behind the elicitation of the rapid and efficient adaptive immune response that leads to acute rejection of allografts.
Transfer of extracellular vesicles boosts direct allorecognition in transplantation
As mentioned in the Introduction, the concept that donor APCs mobilized from allografts (as passenger leukocytes) present by themselves donor MHC molecules to directly alloreactive T cells has been questioned in recent years. Two recent studies have demonstrated in mice that no or extremely few donor passenger APCs are detected in the graftdraining lymphoid organs after transplantation of fully mismatch skin or heterotopic (abdomen) heart grafts, respectively [ (Fig. 1) . The extracellular vesicles transferred from the donor cells were identified as exosomes based on their size (76 AE 32 nm in diameter) and positivity for the exosome markers CD63 and CD9 [3 && ]. The donor-derived exosomes remained bound to the surface of the recipient dendritic cells for hours, or were endocytosed by the recipient APCs for further processing of the donor antigen for presentation via the indirect pathway, or for degradation [3 && ]. The donor exosomes did not seem to fuse with the surface membrane of the recipient dendritic cells, which explains the observation that the donor MHC molecules were not detected incorporated in the plasma membrane of the recipient dendritic cells [3 && ]. Importantly, the donor MHC molecules transferred to recipient APCs were functional. Indeed, within 3 days of heart transplantation, flow cytometry-sorted recipient splenic conventional dendritic cells cross-dressed in vivo with donor exosomes triggered ex-vivo proliferation and effector cell differentiation of directly alloreactive CD8 T cells in mice [3 && ]. In vivo, passage of red fluorescent protein-tagged exosomes from i.v. administered BALB/c fully mature dendritic cells to yellow fluorescent protein-tagged conventional dendritic cells resident in the spleen of C57Bl/6 mice increased expression of host MHC class-II molecules, CD40, CD80 and CD86, but not programmed death-ligand 1 (PD-L1), by the host dendritic cells [3 && ]. Thus, exosomes released by donor-migrating dendritic cells transfer donor MHC molecules to the recipient APCs through exosomes, which also augment the T-cell allostimulatory capacity of the acceptor dendritic cells. Interestingly, exosomes released by mature dendritic cells carry functional membrane-bound tumor necrosis factor-a, a potent dendritic cell-activating cytokine [31] . In support of a role of the recipient APCs in presentation of donor MHC molecules to donor-reactive T cells in graft-draining lymphoid organs, ablation of recipient conventional dendritic cells after heart transplantation decreased severely presentation of donor intact MHC molecules to directly alloreactive T cells via the semidirect pathway, and delayed significantly acute allograft rejection in mice [3 && ]. The available evidence indicates that donorderived extracellular vesicles that cross-dress the recipient APCs in draining lymphoid organs are released by the passenger leukocytes, donor cells within the graft or both [3
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&& ] (Fig. 1) . It is likely that in those allografts where donor passenger leukocytes are unable to migrate out of the transplant (i.e. nonvascularized skin allografts in untreated mice), donor-derived extracellular vesicles leaked in the graft bed traffic passively through the severed openings of recipient lymphatic capillaries toward the graft-draining lymphoid organs [4 && ]. These extracellular vesicles could derive from donor passenger cells trapped in the transplant, or endothelial, parenchymal or nonmigratory stromal cells from the allograft. A recent study has shown that exosomes are efficiently carried across the lymphatic endothelium in vitro, and are rapidly transported within lymphatic vessels in vivo [32 & ]. Interestingly, exosomes by themselves can stimulate lymphatic vessel formation [33] . Apart from the cellular source of the donor extracellular vesicles, the type of donor extracellular vesicles secreted and the relevance of cross-dressing with donor extracellular vesicles on the semidirect pathway may differ depending on the type of organs, tissues or cells transplanted. Extracellular vesicles may also transfer autoantigens that promote graft rejection. Indeed, serum-deprived endothelial cells release exosome-like extracellular vesicles enriched in the LG3 fragment of the autoantigen perlecam, a vascular extracellular matrix protein [34 && ]. The LG3-enriched extracellular vesicles trigger anti-LG3 antibody production and accelerate rejection of aorta allografts in mice [34 && ].
Exosome transfer and split tolerance to noninherited maternal antigens
The idea that no or extremely few donor passenger APCs can have an enormous impact on acute rejection of the allograft by means of a semidirect, exosome-based mechanism led us to inquire whether such a mechanism could account for the enormous impact of MMc. It has long been known that very few maternal cells (on the order of 1 in 10 000 to 1 in 1 000 000) persist in the offspring of a normal mammalian pregnancy. This extremely low proportion of allogeneic cells has a profound impact on the offspring's immune system, as it has been associated with the development of tolerance toward noninherited maternal antigens (NIMAs) [35] [36] [37] . An interesting quality of this tolerogenic impact has been described: it is a split tolerance phenomenon, in which direct allorecognition is functional [38, 39] and associated with increase in episodes of acute rejection [40] , whereas the indirect pathway is regulated/anergized [41] in such a way that, once the acute episodes are overcome, a chronic metastable allotolerance is developed [40] . Because of its 'split' quality, the impact of NIMAs on the T cells of the offspring can play a role in both the prevention of chronic GVHD [42] and the graft versus leukemia effect [43] in hematopoietic stem cell transplantation. The presence of rare maternal cells can be detected directly by PCR and indirectly by some unusual features of the host myeloid dendritic cells (mDCs). These mDCs are the ones that are known from the work of Herrera et al. [9] to retain the allogeneic MHC molecules as intact antigen-presenting molecules after exposure to allogeneic cells. The same study demonstrated that such MHC molecule acquisition occurs, to some extent, independently of cell-cell contact. This phenomenon was first noticed in a murine model of NIMA effect by Zhang and Miller [44] in 1993 although it was then misinterpreted as retention of intact maternal cells rather than 'cross-dressing' of host cells. Dutta et al. ). These 'crossdressed' cells were sometimes in quite high frequency -as much as 20% of the total CD11c þ cell compartment [35] .
This observation of acquired antigen in NIMA dexposed offspring led us to investigate the phenomenon of semidirect pathway and its impacts on allograft rejection and tolerance. First, we noticed that there were differences in the level, the organ distribution and the quality of MMc among the NIMA d offspring after DBA/2 (H-2 d ) heart transplantation [45] . When the backcross breeding was done in such a way that maternal cells could be tagged by green fluorescent protein (GFP), we found that higher levels of MMc were associated with tolerance to a subsequent DBA/2 heart allograft; the presence of immune regulatory cells specific for the NIMA d antigen in spleen and lymph nodes; and the presence of green fluorescent protein þ maternal cells in CD11b þ and CD11c þ myeloid cell populations [45] . As CD11c þ dendritic cells are also known to be capable of secreting large numbers of extracellular vesicles/exosomes, we tested whether the serum of the offspring contained MHC antigens in the form of extracellular vesicles [46 && ]. We found that we could divide the NIMA d -exposed offspring into two types -one type, with low levels of MMc, had no membrane-bound alloantigen acquisition (mAAQ) on the surface of their mDCs (hereafter referred to as 'non-mAAQ' mice). ELISA for the IE molecule, an MHC class-II molecule not expressed in H2 bxb mice, but produced by MMc cells of BDF1 origin, showed that it was present only in the extracellular vesiclefree (100 000 Â g supernatant) fraction of serum in non-mAAQ mice. In mice with membrane alloantigen acquisition (mAAQ þ ), by contrast, the IE molecule was present both in the extracellular vesiclefree serum fraction and the ultracentrifuge pellet containing extracellular vesicles. Analyses of extracellular vesicles-enriched fractions showed the presence of exosome-sized vesicles (50-110 nm diameter), enriched for the exosome marker CD9, with low content of Golgi, endoplasmic reticulum and histone proteins [46 && ]. Furthermore, when extracellular vesicles from the mAAQ þ serum were tested in a short-term culture with B6 (H2 d-negative ) cells, both plasmacytoid dendritic cells (pDCs) and mDCs were found to acquire surface H2-K d (MHC class-I) and IA d (MHC class-II) molecules of maternal origin. Extracellular vesicles from serum of nonmAAQ mice had no such effect. However, this did not mean that non-mAAQ dendritic cells lacked NIMA-presenting capacity. Indeed, the non-mAAQ mice, when analyzed for the expression of the IEa 52-68 allopeptide/IA b complex (i.e. the YAe epitope), had even greater expression on the surface of pDCs, as compared with pDCs of mAAQ þ offspring. In addition, there was a significantly lower expression of the coinhibitory molecule, PD-L1 on the surface of non-mAAQ pDCs versus pDCs from mAAQ þ mice. d molecules were present in precisely the same sector on the surface of the mDCs that had acquired antigen. However, PD-L1, a major coinhibitory molecule, was prominent over the rest of the surface of the mDCs, but was not associated with the acquired MHC alloantigens. In contrast, the CD86 costimulating molecule was associated with the patches of K d and IA d . There remained the puzzle of how a TEa cell specific for the indirect pathway epitope recognized by the YAe antibody could be so strongly inhibited at the same time that the 4C cell was being activated. Close examination of the YAe epitope using imaging flow cytometry relation to PD-L1 showed that there were zones of overlap between the YAe labeling and the PD-L1 signal. This led us to postulate that the reason for the inability of mAAQ þ mDCs to productively activate the TEa indirect pathway T helper cell was the result of a PD-L1-dependent anergy. To test this, mDCs and pDCs were isolated from the spleens of non-mAAQ and mAAQ þ mice. As expected, nonmAAQ dendritic cells caused proliferation of the TEa cells, with or without the addition of PD-L1 blocking antibody, whereas no proliferation above background was seen with the 4C direct pathway responders. When mAAQ þ mDCs and pDCs were used, we detected strong proliferation of the 4C cells, and no division of the TEa cells, as predicted by the in-vivo proliferation results. However, the addition of an antibody against the PD-L1 coinhibitory ligand restored a strong proliferative response to both pDCs and mDCs of mAAQ þ offspring [46 && ]. We propose that the MMc-derived extracellular vesicles, upon interaction with host dendritic cells, have opposite impacts upon the functionality of the indirect and semidirect pathways of T-cell allorecognition, which become anergized and primed, respectively. Exactly how maternal extracellular vesicles perform this 'trick', so different from the strong expression of positive costimulation, with no PD-L1, on host dendritic cells cross-dressed by passenger leukocyte-derived extracellular vesicles in acute rejection [3 && ], is still to be determined.
CONCLUSION
These findings identify cross-dressing via clusters of exosomes as an explanation for the potency of alloimmunity, unveil a new role of extracellular vesicles in the elicitation of the semidirect pathway of allorecognition and open new possibilities for the development of therapies to treat transplant rejection or to reinforce tolerance that may be based on microchimerism. The semidirect pathway was originally proposed by Jiang et al. [47] as a solution to the so-called '4 cell problem' in transplantation, that is how indirect pathway CD4 T 'help' could be provided to a direct pathway CD8 CTL, something that had been clearly demonstrated 10 years earlier [48] . The phenomenon of alloantigen acquisition by host dendritic cells was able to reduce this to a three- cell (T helper cell-dendritic cell-CTL) interaction. Table 2 summarizes the two types of semidirect pathway outlined in this article, and how what the extracellular vesicles do to alter indirect pathway T-cell 'help' impacts acute rejection and maternally induced spilt tolerance. The mechanistic basis of MMc-associated split tolerance, and that of alloactivation leading to acute rejection, appears to both revolve around extracellular vesicles and the semidirect pathway, opening venues for new therapeutic and diagnostic approaches in transplantation.
